General
Preferred name
daunorubicin
Synonyms
DAUNORUBICIN HYDROCHLORIDE ()
RP 13057 ()
Rubidomycin ()
Daunomycin ()
RP-13057 Hydrochloride ()
Rubidomycin hydrochloride ()
Daunorubicin HCl ()
Daunomycin HCl ()
Daunorubicin (HCl) ()
RP13057 ()
RP 13057 Hydrochloride ()
RP13057 Hydrochloride ()
Cerubidine ()
Daunorubicin (Hydrochloride) ()
DAUNORUBICIN CITRATE ()
Daunomycin (Hydrochloride) ()
RP 13057 (Hydrochloride) ()
Rubidomycin (Hydrochloride) ()
Daunorubicin (RP 13057) HCl ()
Daunomycin HCl, Rubidomycin HCl ()
FI 6339 HYDROCHLORIDE ()
NDC 0082-4155 ()
RP-13057 ()
RP-13057 HYDROCHLORIDE ()
NSC-82151 ()
FI-6339 HYDROCHLORIDE ()
RP 13057 HYDROCHLORIDE ()
FI-6339 ()
NDC-0082-4155 ()
FI 6339 [AS THE BASE] ()
RP 13057 [AS THE BASE) ()
Daunorubicin (as hydrochloride) ()
Daunoxome ()
Valrubicin impurity, daunorubicin ()
NSC-83142 ()
FI 6339 ()
Epirubicin hydrochloride impurity, daunorubicin- ()
Daunorubicin citrate liposome ()
Daunorubicin liposomal ()
Daunorubicin-13C-d3 ()
P&D ID
PD009842
CAS
20830-81-3
23541-50-6
11016-72-1
1407-15-4
11006-54-5
Tags
nuisance
natural product
drug
available
Approved by
PMDA
FDA
First approval
1979
1996
Drug Status
approved
Drug indication
Acute myeloid leukaemia
Antineoplastic
Kaposi sarcoma
Solid tumour/cancer
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Daunorubicin is an anthracycline class chemotherapeutic for cancer treatment.
Daunorubicin is on the World Health Organisation's List of Essential Medicines. Click here to access the pdf version of the WHO's 21st Essential Medicines list (2019). (GtoPdb)
Cell lines
71
Organisms
5
Compound Sets
24
AdooQ Bioactive Compound Library
A10194
Cayman Chemical Bioactives
14159
29101
ChEMBL Approved Drugs
CHEMBL1563
CHEMBL178
CHEMBL1200475
ChEMBL Drugs
CHEMBL1563
CHEMBL178
CHEMBL1200475
Drug Repurposing Hub
DrugBank
DB00694
DrugBank Approved Drugs
DB00694
DrugCentral
786
DrugCentral Approved Drugs
786
DrugMAP
DMQUSBT
DrugMAP Approved Drugs
DMQUSBT
EU-OPENSCREEN Bioactive Compound Library
EOS101591
Guide to Pharmacology
7063
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1563
CHEMBL178
MedChem Express Bioactive Compound Library
HY-13062
NCATS Inxight Approved Drugs
ZS7284E0ZP
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
daunorubicin-hcl-daunomycin-hcl
TargetMol Bioactive Compound Library
T1511
The Spectrum Collection
ZINC Tool Compounds
ZINC000003917708
External IDs
107
Properties
(calculated by RDKit )
Molecular Weight
527.18
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
5
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
2
cLogP
1.03
TPSA
185.84
Fraction CSP3
0.44
Chiral centers
6.0
Largest ring
6.0
QED
0.31
Structural alerts
3
quinone_A(370)
[!#6&!#1]=[#6]-1-[#6]=,:[#6]-[#6](=[!#6&!#1])-[#6]=,:[#6]-1
PAINS Family A
Intercalation
Nuisance compounds in cellular assays
Optical interference
Fluorescence
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Target
Topoisomerase
ADC Cytotoxin
DNA/RNA Synthesis
Autophagy
DNA synthesis
TOP2A, TOP2B
antibiotic
Bacterial
ADC Cytotoxin,Antineoplastic and Immunosuppressive Antibiotics,Apoptosis related,COVID-19,DNA/RNA Synthesis,Topoisomerase
Pathway
Cell Cycle/DNA Damage
Antibody-drug Conjugate/ADC Related
DNA Damage/DNA Repair
Anti-infection
Apoptosis
Indication
acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)
MOA
RNA synthesis inhibitor, topoisomerase inhibitor
Therapeutic Class
Anticancer Agents
Source data